Appointments

Novel obesity treatment-focused biopharmaceutical company Antag Therapeutics has announced the appointment of Joerg Moeller MD PhD as chief executive officer. Dr Moeller replaces Antag co-founder Dr Alexander Sparre-Ulrich, who will continue in the company as chief operating officer.

Dr Moeller has over 30 years of leadership and industry experience, including in bringing first-inclass therapies to market across a wide range of therapeutic areas including, oncology, haematology, ophthalmology, female health, dermatology and infectious diseases. He was previously head of global R&D at Bayer AG’s pharmaceutical division.

Philip Just Larsen MD PhD, chair of Antag Therapeutics board of Directors, said: “Dr Moeller has a proven track record in pharmaceutical innovation and pioneering cutting-edge biotech solutions, and has the experience to drive Antag to its next phase of growth as we prepare to enter clinical development with our lead candidate,

AT-7687. On behalf of the board, I want to thank Alexander for his exceptional contributions in founding and leading Antag into this critical stage of drug development. His work has laid a strong foundation for future success as we continue our commitment to delivering transformative therapies with the potential to improve patient outcomes and address the growing global burden of obesity and metabolic disorders.”

Joerg Moeller MD, newly appointed CEO of Antag Therapeutics, commented: “Antag’s innovative approach and new mechanism of action in obesity treatment, rooted in pioneering GIP receptor antagonism, holds tremendous potential to address the global rise of people living with obesity and improve the current standard of care. I look forward to working with Alexander and Antag’s stellar leadership team as we advance our pipeline of injectable therapies, striving to benefit patients suffering from obesity and cardiometabolic diseases.”